Newco Avidicure NV arrived on the scene with a hefty $50 million in seed funding to advance novel antibody formats the company says will surpass the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers and antibody-drug conjugates.
Korea Institute of Science and Technology has identified ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer.
Shanghai Yingli Pharmaceutical Co. Ltd. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Immune checkpoint inhibitors have revolutionized cancer therapy by reversing tumor-induced immunosuppression, but they fail to work for many patients because of resistance. In addition, they can reactivate immune pathways only from outside immune cells.
Metastatic castration-resistant prostate cancer (mCRPC) is driven by molecular and genetic alterations in multiple signaling pathways and usually progresses despite initial response to androgen deprivation therapy.
Prostate cancer, the second most frequent malignancy among men worldwide, can be treated using various antagonists of the androgen receptor, but many patients develop resistance within 18-24 months, and the resistance can block efficacy of not only the first-line antagonist but later-line antagonists as well. Therefore next-generation antagonists based on novel scaffolds are urgently needed.
Minerva Biotechnologies Corp. recently released details on their work to develop a treatment for HER2-positive patients who have acquired resistance to Herceptin (trastuzumab) or Enhertu (trastuzumab-deruxtecan).
Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of cases of pancreatic cancer, and prognosis for PDAC remains poor despite treatment advances. One reason is that PDAC downregulates the display of antigens on the surface of tumor cells, helping it evade the patient’s immune system and therapies involving immune checkpoint inhibitors.
RSS
